日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial

在1型糖尿病成人患者中,SAR341402胰岛素门冬与原研胰岛素门冬转换治疗与持续使用原研胰岛素门冬相比的安全性和有效性:GEMELLI X试验

Shah, Viral N; Al-Karadsheh, Amer; Barnes, Cathy; Mandry, Jose; Nakhle, Samer; Wernicke-Panten, Karin; Kramer, Daniel; Schmider, Wolfgang; Pierre, Suzanne; Teichert, Lenore; Rotthaeuser, Baerbel; Mukherjee, Bhaswati; Bailey, Timothy S

Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M)

生物类似药胰岛素门冬预混剂 SAR341402 Mix 70/30 与原研胰岛素门冬混合剂 70/30 (NovoMix 30) 在糖尿病患者中的疗效比较:一项为期 26 周的随机、开放标签试验 (GEMELLI M)

Aravind, S R; Singh, Kiran P; Aquitania, Grace; Mogylnytska, Liliia; Zalevskaya, Alsu G; Matyjaszek-Matuszek, Beata; Wernicke-Panten, Karin; Nguyên-Pascal, My-Liên; Pierre, Suzanne; Rotthaeuser, Baerbel; Kramer, Daniel; Mukherjee, Bhaswati

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin

生物类似药胰岛素门冬预混剂SAR341402 70/30与原研胰岛素门冬预混剂70/30在糖尿病成人患者中的疗效、安全性和免疫原性比较(GEMELLI M):按既往使用预混剂类型进行的亚组分析

Aravind, S R; Singh, Kiran P; Mogylnytska, Liliia; Zalevskaya, Alsu G; Matyjaszek-Matuszek, Beata; Wernicke-Panten, Karin; Nguyên-Pascal, My-Liên; Pierre, Suzanne; Rotthaeuser, Baerbel; Kramer, Daniel; Mukherjee, Bhaswati

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump

通过胰岛素泵给药时赖脯胰岛素及其生物类似药的安全性

Thrasher, James; Surks, Howard; Nowotny, Irene; Pierre, Suzanne; Rotthaeuser, Baerbel; Wernicke-Panten, Karin; Garg, Satish